Eversept Partners LP Invests $1.26 Million in Evommune, Inc. $EVMN

Eversept Partners LP acquired a new stake in Evommune, Inc. (NYSE:EVMN) during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 54,680 shares of the company’s stock, valued at approximately $1,257,000. Eversept Partners LP owned approximately 0.15% of Evommune at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of EVMN. Capricorn Fund Managers Ltd purchased a new position in Evommune in the fourth quarter valued at approximately $1,027,000. Sofinnova Investments Inc. purchased a new stake in Evommune during the fourth quarter worth approximately $2,625,000. Seven Grand Managers LLC acquired a new stake in shares of Evommune in the fourth quarter worth $1,284,000. NEXTBio Capital Management LP acquired a new stake in shares of Evommune in the fourth quarter worth $3,908,000. Finally, EQT Fund Management S.a r.l. acquired a new position in shares of Evommune during the 4th quarter valued at $84,395,000.

Insider Buying and Selling at Evommune

In other Evommune news, Director Arthur S. Kirsch bought 10,000 shares of the company’s stock in a transaction dated Tuesday, July 7th. The shares were acquired at an average cost of $13.30 per share, with a total value of $133,000.00. Following the completion of the transaction, the director owned 10,000 shares in the company, valued at $133,000. The trade was a ? increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Luis C. Pena sold 7,438 shares of the stock in a transaction dated Monday, June 22nd. The shares were sold at an average price of $22.71, for a total value of $168,916.98. Following the completion of the transaction, the chief executive officer directly owned 630,458 shares of the company’s stock, valued at $14,317,701.18. This represents a 1.17% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 100,854 shares of company stock valued at $2,279,142. Company insiders own 31.10% of the company’s stock.

Evommune Trading Up 0.8%

EVMN opened at $11.45 on Tuesday. The company has a fifty day simple moving average of $17.90 and a 200 day simple moving average of $21.63. The firm has a market cap of $412.36 million and a price-to-earnings ratio of -1.21. Evommune, Inc. has a twelve month low of $10.47 and a twelve month high of $33.20.

Evommune (NYSE:EVMN) last released its quarterly earnings results on Thursday, May 7th. The company reported ($0.64) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.83) by $0.19. On average, analysts forecast that Evommune, Inc. will post -2.83 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of analysts recently weighed in on EVMN shares. William Blair cut shares of Evommune from an “outperform” rating to a “market perform” rating in a research report on Monday, June 29th. Stifel Nicolaus assumed coverage on Evommune in a research report on Friday, May 1st. They issued a “buy” rating and a $54.00 price objective on the stock. Wall Street Zen cut Evommune from a “hold” rating to a “sell” rating in a research note on Saturday, June 13th. Weiss Ratings lowered Evommune from a “sell (d)” rating to a “sell (d-)” rating in a research note on Monday, June 29th. Finally, Oppenheimer started coverage on Evommune in a report on Tuesday, April 7th. They set an “outperform” rating and a $50.00 target price on the stock. Two analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $45.62.

Evommune Company Profile

Evommune is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria (“CSU”), atopic dermatitis (“AD”) and ulcerative colitis (“UC”). Chronic inflammation is a significant healthcare problem in the world, substantially impacting patients’ quality of life and leading to life-threatening conditions. These conditions, if not prevented, ultimately lead to fatal diseases, such as cardiovascular diseases, diabetes and cancer, which contribute to three out of every five deaths worldwide and result in an estimated $90 billion of annual cost to the healthcare system in the United States.